Ag - biologicals

Search documents
Evogene Announces Completion of Transaction for the Sale of Lavie Bio's Activity to ICL
Prnewswire· 2025-07-08 11:00
Core Insights - Evogene Ltd. has successfully completed the divestiture of the majority of its ag-biologicals subsidiary, Lavie Bio Ltd., to ICL Group Ltd., which includes the transfer of Evogene's MicroBoost AI for AG platform [1][2][4] - The transaction encompasses Lavie Bio's proprietary Biology Driven Design technology platform, microbial bank, advanced development programs, and current commercial products, along with core personnel transferring to ICL [2][4] - Existing strategic partnerships and commercial agreements of Lavie Bio will remain under its ownership, potentially generating future revenues for its shareholders [3] Company Strategy - The divestment aligns with Evogene's broader corporate strategy to unlock the intrinsic value of its subsidiaries and technology [4] - ICL aims to enhance its position in the global ag-biologicals market by integrating Lavie Bio's capabilities with its own R&D expertise and sales network, thereby advancing sustainable agricultural solutions [4] Technological Overview - Evogene utilizes three technological engines: MicroBoost AI, ChemPass AI, and GeneRator AI, focusing on the discovery and development of products based on microbes, small molecules, and genetic elements respectively [5] - The company aims to revolutionize life-science product development by leveraging big data and artificial intelligence to increase success rates while reducing development time and costs [5]
ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio
Prnewswire· 2025-04-21 11:00
"Today marks a significant milestone in Lavie Bio's journey," said Amit Noam, CEO of Lavie Bio. "By combining our capabilities with ICL's expertise, we can further accelerate the development of groundbreaking ag-biological products that will provide innovative solutions to farmers around the world." This transaction follows strategic investment by ICL Planet and more than two years of close collaboration between ICL and Lavie Bio, focused on developing innovative bio-stimulant solutions for row crops facing ...
ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio
Prnewswire· 2025-04-21 11:00
Core Insights - Lavie Bio is a leader in the ag-biologicals industry with a strong pipeline of microbiome-based products [1] - ICL will acquire key assets from Lavie Bio, including its core team, BDD technology platform, microbial bank, and commercial products [1] - The transaction follows over two years of collaboration between ICL and Lavie Bio to develop bio-stimulant solutions for crops [2] - The integration aims to accelerate the development of innovative ag-biological products for global agriculture [3] Company Overview - Lavie Bio, a subsidiary of Evogene Ltd., focuses on enhancing food quality and agricultural productivity through microbiome-based products [4] - The company utilizes a proprietary computational predictive platform, the BDD platform, powered by Evogene's MicroBoost AI technology [4] - Evogene Ltd. aims to revolutionize life-science product development using advanced technologies to improve success rates and reduce costs [6] Strategic Implications - The acquisition is expected to significantly advance the global ag-biologicals field and foster impactful agricultural innovations [3] - Existing agreements between Lavie Bio and its partners will remain with Lavie Bio, potentially generating future revenue for its shareholders [1]